Drug Profile


Alternative Names: CMS-024-02

Latest Information Update: 08 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator China Medical System; Shenzhen Kangzhe Pharmaceutical
  • Developer Shenzhen Kangzhe Pharmaceutical
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 31 Mar 2007 CMS files an application for approval of a phase II trial with China's State FDA for non-small lung cancer
  • 30 Nov 2006 CMS completes a phase I trial in non-small cell lung cancer in China
  • 31 Mar 2006 Phase-I clinical trials in Non-small cell lung cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top